Wellington Management Group LLP Cuts Stock Holdings in Charles River Laboratories International, Inc. $CRL

Wellington Management Group LLP reduced its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 20.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,288,463 shares of the medical research company’s stock after selling 340,938 shares during the quarter. Wellington Management Group LLP owned 2.70% of Charles River Laboratories International worth $292,211,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. Jones Financial Companies Lllp grew its position in Charles River Laboratories International by 167.6% during the 1st quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock worth $253,000 after acquiring an additional 1,074 shares during the last quarter. Empowered Funds LLC bought a new stake in Charles River Laboratories International in the first quarter valued at approximately $418,000. American Century Companies Inc. boosted its stake in shares of Charles River Laboratories International by 41.9% during the second quarter. American Century Companies Inc. now owns 5,469 shares of the medical research company’s stock valued at $830,000 after purchasing an additional 1,616 shares during the period. Brown Advisory Inc. boosted its stake in shares of Charles River Laboratories International by 5.1% during the second quarter. Brown Advisory Inc. now owns 2,333 shares of the medical research company’s stock valued at $354,000 after purchasing an additional 114 shares during the period. Finally, California Public Employees Retirement System grew its holdings in shares of Charles River Laboratories International by 3.9% in the second quarter. California Public Employees Retirement System now owns 84,605 shares of the medical research company’s stock worth $12,837,000 after purchasing an additional 3,198 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Up 0.1%

NYSE:CRL opened at $291.80 on Monday. The company has a 50-day moving average price of $246.06 and a 200-day moving average price of $197.39. The stock has a market cap of $13.93 billion, a price-to-earnings ratio of -60.16, a P/E/G ratio of 3.03 and a beta of 1.38. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.92. Charles River Laboratories International, Inc. has a 12 month low of $144.26 and a 12 month high of $303.30.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The company had revenue of $1 billion for the quarter, compared to analysts’ expectations of $980.53 million. During the same quarter in the previous year, the company earned $3.12 earnings per share. Charles River Laboratories International’s quarterly revenue was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Equities analysts predict that Charles River Laboratories International, Inc. will post 11.33 EPS for the current year.

Key Stories Impacting Charles River Laboratories International

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Long-term earnings outlook improved. Zacks Research raised its EPS forecasts for fiscal 2026 to $11.15 from $10.91, fiscal 2027 to $12.49 from $12.11, and fiscal 2028 to $13.82 from $13.01. Estimates also increased for several future quarters, signaling greater confidence in CRL’s longer-term growth prospects.
• Positive Sentiment: Enterovirus vaccine collaboration could generate future demand. Medigen has partnered with Charles River in an effort to bring an enterovirus vaccine to global markets. The initiative could create additional opportunities for CRL’s contract research, testing, and development services. Medigen links up with Charles River in push to take enterovirus vaccine global
• Neutral Sentiment: Recent operating results provide a mixed backdrop. CRL’s latest quarterly EPS of $3.02 exceeded the $2.77 consensus estimate, and revenue reached approximately $1 billion. However, revenue declined 2.7% year over year, while the company’s full-year 2026 EPS guidance remains $11.15-$11.45, close to the analyst consensus.
• Negative Sentiment: Director sold a sizable stake. James C. Foster sold 33,561 shares for about $10.1 million at an average price of $300, reducing his direct ownership by 51.5%. The transaction was made under a pre-arranged Rule 10b5-1 plan, which makes it a less definitive bearish signal, but the size of the sale may pressure investor sentiment. SEC insider transaction filing
• Negative Sentiment: Some near-term estimates were lowered. Zacks trimmed its EPS forecasts for the third and fourth quarters of 2026, the first quarter of 2027, and the fourth quarter of 2027. These modest cuts suggest near-term uncertainty despite the stronger full-year and longer-term projections.

Wall Street Analyst Weigh In

Several research analysts recently commented on CRL shares. Piper Sandler set a $300.00 target price on shares of Charles River Laboratories International in a research note on Monday, August 10th. Barclays reissued an “overweight” rating and issued a $300.00 price target on shares of Charles River Laboratories International in a report on Wednesday, August 5th. CLSA cut shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price objective on the stock. in a research report on Monday, July 20th. Evercore reaffirmed an “outperform” rating on shares of Charles River Laboratories International in a research note on Wednesday, August 5th. Finally, Robert W. Baird set a $291.00 target price on shares of Charles River Laboratories International in a report on Thursday, August 6th. Twelve investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Charles River Laboratories International has an average rating of “Moderate Buy” and an average target price of $255.65.

Insider Activity

In related news, CEO Birgit Girshick sold 6,500 shares of Charles River Laboratories International stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $279.90, for a total transaction of $1,819,350.00. Following the sale, the chief executive officer directly owned 36,013 shares in the company, valued at $10,080,038.70. The trade was a 15.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director James C. Foster sold 75,000 shares of the company’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $225.00, for a total value of $16,875,000.00. Following the completion of the sale, the director directly owned 31,596 shares in the company, valued at approximately $7,109,100. The trade was a 70.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 165,990 shares of company stock worth $42,606,388. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.